Literature DB >> 2211259

Limb salvage in soft tissue sarcomas involving neurovascular structures using combined surgical resection and brachytherapy.

M J Zelefsky1, D Nori, M H Shiu, M F Brennan.   

Abstract

While there is debate in the literature concerning the tolerance of neurovascular structures to external beam radiation, the tolerance of these tissues to interstitial radiation has never been established. To evaluate the dose of radiation and its effect on early and late toxicity of neurovascular structures, a retrospective review of our experience was undertaken. Between 1975 and 1987, 299 patients with extremity sarcomas underwent limb-sparing surgery and tumor bed Iridium-192 interstitial implantation at Memorial Sloan-Kettering Cancer Center. Forty-five patients (15%) of this group were found to have locally advanced tumors involving major neurovascular structures. Of these patients, 64% had high grade lesions. Eleven percent had evidence of gross residual disease on these structures, and an additional 58% had microscopic residual disease at or close to the margins of resection. After loading catheters were placed directly upon the neurovascular structures in the exposed tumor bed and a median dose of 4400 cGy was delivered to the target volume. Eight patients had previous radiation to the treated field and 13 patients received postoperative radiation. With a median follow-up of 4 years, the 5-year actuarial disease-free survival was 69% and the 5-year actuarial freedom from in-field failure was 79%. The 5-year actuarial incidence of distant metastases was 30%. Eighty-four percent of the patients maintained long-term preservation of limb function without the need for amputation. Four patients (9%) ultimately developed evidence of radiation neuritis 6-20 months post therapy. All four patients had received additional radiation with cumulative doses exceeding 9000 cGy to the neurovascular bundle. We conclude that combined surgical resection and interstitial radiation for locally advanced sarcomas with neurovascular involvement can provide excellent local control with preservation of limb and neurovascular function without significant toxicity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2211259     DOI: 10.1016/0360-3016(90)90012-9

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  5 in total

1.  Implications of staged reconstruction and adjuvant brachytherapy in the treatment of recurrent soft tissue sarcoma.

Authors:  Arash O Naghavi; Ricardo J Gonzalez; Jacob G Scott; John E Mullinax; Yazan A Abuodeh; Youngchul Kim; Odion Binitie; Kamran A Ahmed; Marilyn M Bui; Amarjit S Saini; Jonathan S Zager; Matthew C Biagioli; Douglas Letson; Louis B Harrison; Daniel C Fernandez
Journal:  Brachytherapy       Date:  2016-05-12       Impact factor: 2.362

2.  Immediate versus delayed free-tissue transfer salvage of the lower extremity in soft tissue sarcoma patients.

Authors:  G P Reece; M A Schusterman; R E Pollock; S S Kroll; M J Miller; B J Baldwin; M M Romsdahl; N A Janjan
Journal:  Ann Surg Oncol       Date:  1994-01       Impact factor: 5.344

3.  Nerve tolerance to high-dose-rate brachytherapy in patients with soft tissue sarcoma: a retrospective study.

Authors:  Tadahiko Kubo; Takashi Sugita; Shoji Shimose; Toshihiro Matsuo; Ken Hirao; Hiroaki Kimura; Masahiro Kenjo; Mitsuo Ochi
Journal:  BMC Cancer       Date:  2005-07-19       Impact factor: 4.430

4.  Adjuvant Radiation Therapy of Retroperitoneal Sarcoma: The Role of Intraoperative Radiotherapy (IORT).

Authors:  K S Hu; L C Harrison
Journal:  Sarcoma       Date:  2000

5.  Study of Preoperative Radiotherapy for Sarcomas of the Extremities with Intensity-Modulation, Image-Guidance and Small Safety-margins (PREMISS).

Authors:  Barbara Röper; Christine Heinrich; Victoria Kehl; Hans Rechl; Katja Specht; Klaus Wörtler; Andreas Töpfer; Michael Molls; Severin Kampfer; Rüdiger von Eisenharth-Rothe; Stephanie E Combs
Journal:  BMC Cancer       Date:  2015-11-16       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.